Table 3 Acute and Choronic Adverse Effects for Patients Treated With VBT alone or EBRT (with or without VBT)
|  | Patients (N = 899) | |||||
|---|---|---|---|---|---|---|
Early Adverse Effects | Late Adverse Effects | |||||
VBT alone (n = 499) | EBRT (with or without VBT) (n = 400) | p | VBT alone (n = 499) | EBRT (with or without VBT) (n = 400) | p | |
Adverse Events | No. (%) | No. (%) | Â | No. (%) | Â | Â |
GI | Â | Â | 0.000 | Â | Â | 0.001 |
 0 | 293 (73.3) | 114 (22.8) |  | 358 (89.5) | 406 (81.4) |  |
 1–2 | 107 (26.8) | 382 (76.6) |  | 41 (10.3) | 92 (18.4) |  |
 3–4 | 0 (0.0) | 3 (0.6) |  | 1 (0.3) | 1 (0.2) |  |
Urinary Tract | Â | Â | 0.000 | Â | Â | 0.003 |
 0 | 376 (94.0) | 416 (83.4) |  | 384 (96.0) | 453 (90.8) |  |
 1–2 | 24 (6.0) | 82 (16.4) |  | 16 (4.0) | 45 (9.0) |  |
 3–4 | 0 (0.4) | 1 (0.6) |  | 0 (0.0) | 1 (0.2) |  |
Hematological | Â | Â | 0.000 | Â | Â | 0.005 |
 0 | 371 (92.8) | 271 (54.3) |  | 383 (95.8) | 456 (91.4) |  |
 1–2 | 29 (7.2) | 204 (40.9) |  | 15 (3.8) | 42 (8.4) |  |
 3–4 | 0 (0.0) | 24 (4.8) |  | 2 (0.5) | 1 (0.2) |  |
Edema | Â | Â | Â | Â | Â | 0.000 |
 0 | / | / |  | 379 (94.8) | 428 (85.8) |  |
 1–2 | / | / |  | 21 (5.3) | 71 (14.2) |  |
 3–4 | / | / |  | 0 (0.0) | 0 (0.0) |  |